The number of people with susceptibility test result for rifampicin in United States
United States: The number of people with susceptibility test result for rifampicin was 4,814 in 2021. ▼ Falling
Latest (2021)
4,814
Change on year
up 10.2%
World rank
30th
of 155 countries
All-time high
5,329
in 2019
All-time low
4,370
in 2020
Years of data
5
2017–2021
The number of people with susceptibility test result for rifampicin in United States, 2017–2021
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for the number of people with susceptibility test result for rifampicin in United States is 4,814, measured in 2021.
Compared with earlier readings it is up 10.2% on the previous year and down 7.2% over five years.
That places United States 30th out of 155 countries with data for 2021, putting it in the top quarter.
The number of people with susceptibility test result for rifampicin in United States, year by year
| Year | Value | Change |
|---|---|---|
| 2017 | 5,189 | — |
| 2018 | 5,136 | -1.0% |
| 2019 | 5,329 | +3.8% |
| 2020 | 4,370 | -18.0% |
| 2021 | 4,814 | +10.2% |
United States compared with similar countries
- United States's 4,814 is above the median for high income countries, which is 142, 33.9× the median. (61 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 5,218 | 5,136 | 5,329 | 3 |
| 2020s | 4,592 | 4,370 | 4,814 | 2 |
Countries ranked near United States
More health data for United States
- Un projection of annual infant deaths, annual growth rate -1.67 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.1867 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,069 deaths per 1,000 people (2090)
- Number of infants who die before age 1 4,015 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2023)
- Population ages 00-04, female, annual growth rate 0.056 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0261 units per person (2025)
- Population ages 00-04, male, annual growth rate 0.1919 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is the number of people with susceptibility test result for rifampicin in United States?
- The number of people with susceptibility test result for rifampicin in United States was 4,814 in 2021, according to World Health Organization, Global Health Observatory.
- What is the highest the number of people with susceptibility test result for rifampicin recorded in United States?
- The highest recorded value was 5,329 in 2019.
- What is the lowest the number of people with susceptibility test result for rifampicin recorded in United States?
- The lowest recorded value was 4,370 in 2020.
- How does United States rank for the number of people with susceptibility test result for rifampicin?
- United States ranks 30th out of 155 countries with data for 2021.
- Where does this United States data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 5 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).